Clinical Effectiveness of Idarucizumab in Dabigatran Reversal | Wang | Journal of Cardiology and Therapy
Idarucizumab, the Sequel – Emergency Medicine Literature of Note
Idarucizumab dosing in patients with excessive dabigatran body burden - British Journal of Anaesthesia
Idarucizumab (PRAXBIND) | STROKE MANUAL
Idarucizumab: Plenty of optimism, not enough science - First10EM
Idarucizumab for Emergency Reversal of Anticoagulant Effects of Dabigatran: Interim Results of a Japanese Post-Marketing Surveillance Study | SpringerLink
Design of the Reversal Effects of Idarucizumab on Active Dabigatran... | Download Scientific Diagram
Idarucizumab | Circulation
Effect of Age and Renal Function on Idarucizumab Pharmacokinetics and Idarucizumab-Mediated Reversal of Dabigatran Anticoagulant Activity in a Randomized, Double-Blind, Crossover Phase Ib Study | SpringerLink
Frontiers | Dabigatran Level Before Reversal Can Predict Hemostatic Effectiveness of Idarucizumab in a Real-World Setting
Idarucizumab for Reversal of Dabigatran – Core EM
FDA Approves Praxbind® (idarucizumab), Specific Reversal Agent for Pradaxa® (dabigatran etexilate) | Business Wire
Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised, placebo-controlled, double-blind phase 1 trial - The Lancet
Clinical Evidence | Praxbind® (idarucizumab)
Idarucizumab for Dabigatran Reversal — Full Cohort Analysis - MPR
Interpretation of idarucizumab clinical trial data based on spontaneous reports of dabigatran adverse effects in the French phar
Medicina | Free Full-Text | Effectiveness and Safety of Dabigatran Reversal with Idarucizumab in the Taiwanese Population: A Comparison Based on Eligibility for Inclusion in Clinical Trials
Idarucizumab for Dabigatran Reversal — Full Cohort Analysis | NEJM
Safety, pharmacokinetics and pharmacodynamics of idarucizumab, a specific dabigatran reversal agent in healthy Japanese volunteers: a randomized study - Research and Practice in Thrombosis and Haemostasis
Boehringer Ingelheim submits applications for approval of Idarucizumab, an anti-anticoagulant - Labiotech.eu
Evidence Supporting Idarucizumab for the Reversal of Dabigatran
Idarucizumab for Dabigatran Reversal — Full Cohort Analysis | NEJM
Medicina | Free Full-Text | Effectiveness and Safety of Dabigatran Reversal with Idarucizumab in the Taiwanese Population: A Comparison Based on Eligibility for Inclusion in Clinical Trials
